{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:00:43Z","timestamp":1787731243498,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12185-026-04173-7","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:59:09Z","timestamp":1770789549000},"page":"866-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term clinical outcomes of patients with localized primary ocular adnexal mucosa-associated lymphoid tissue lymphoma"],"prefix":"10.1007","volume":"123","author":[{"given":"Ritsuko","family":"Nakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miyagi-Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenobu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"1","key":"4173_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#","volume":"29","author":"C Freeman","year":"1972","unstructured":"Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29(1):252\u201360.","journal-title":"Cancer"},{"issue":"5","key":"4173_CR2","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/S0360-3016(03)00767-3","volume":"57","author":"CY Fung","year":"2003","unstructured":"Fung CY, Tarbell NJ, Lucarelli MJ, Goldberg SI, Linggood RM, Harris NL, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys. 2003;57(5):1382\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4173_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ajh.10332","volume":"73","author":"EY Cho","year":"2003","unstructured":"Cho EY, Han JJ, Ree HJ, Ko YH, Kang Y, Ahn HS, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol. 2003;73(2):87\u201396.","journal-title":"Am J Hematol"},{"issue":"2","key":"4173_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/01.pas.0000213350.49767.46","volume":"31","author":"JA Ferry","year":"2007","unstructured":"Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, Preffer FI, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31(2):170\u201384.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"4173_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1046\/j.1442-9071.2001.d01-18.x","volume":"29","author":"PA McKelvie","year":"2001","unstructured":"McKelvie PA, McNab A, Francis IC, Fox R, O\u2019Day J. Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Experiment Ophthalmol. 2001;29(6):387\u201393.","journal-title":"Clin Experiment Ophthalmol"},{"issue":"1","key":"4173_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3341\/kjo.2006.20.1.7","volume":"20","author":"JM Woo","year":"2006","unstructured":"Woo JM, Tang CK, Rho MS, Lee JH, Kwon HC, Ahn HB. The clinical characteristics and treatment results of ocular adnexal lymphoma. Korean J Ophthalmol. 2006;20(1):7\u201312.","journal-title":"Korean J Ophthalmol"},{"issue":"1","key":"4173_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2141.2010.08429.x","volume":"152","author":"S Bayraktar","year":"2011","unstructured":"Bayraktar S, Bayraktar UD, Stefanovic A, Lossos IS. Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients. Br J Haematol. 2011;152(1):72\u201380.","journal-title":"Br J Haematol"},{"issue":"3","key":"4173_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0360-3016(01)02729-8","volume":"52","author":"QT Le","year":"2002","unstructured":"Le QT, Eulau SM, George TI, Hildebrand R, Warnke RA, Donaldson SS, et al. Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys. 2002;52(3):657\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4173_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","volume":"92","author":"J Yahalom","year":"2015","unstructured":"Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, et al. International lymphoma radiation oncology group modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):11\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"4173_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cncr.11539","volume":"98","author":"T Uno","year":"2003","unstructured":"Uno T, Isobe K, Shikama N, Nishikawa A, Oguchi M, Ueno N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer. 2003;98(4):865\u201371.","journal-title":"Cancer"},{"issue":"1","key":"4173_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.radonc.2005.11.005","volume":"78","author":"Y Ejima","year":"2006","unstructured":"Ejima Y, Sasaki R, Okamoto Y, Maruta T, Azumi A, Hayashi Y, et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol. 2006;78(1):6\u20139.","journal-title":"Radiother Oncol"},{"issue":"2","key":"4173_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4143\/crt.2017.182","volume":"50","author":"GI Lee","year":"2018","unstructured":"Lee GI, Oh D, Kim WS, Kim SJ, Ko YH, Woo KI, et al. Low-dose radiation therapy for primary conjunctival marginal zone B-cell lymphoma. Cancer Res Treat. 2018;50(2):575\u201381.","journal-title":"Cancer Res Treat"},{"issue":"7","key":"4173_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/jjco\/hyz044","volume":"49","author":"J Lee","year":"2019","unstructured":"Lee J, Yoon JS, Kim JS, Koom WS, Cho J, Suh CO. Long-term outcome, relapse patterns, and toxicity after radiotherapy for orbital mucosa-associated lymphoid tissue lymphoma: implications for radiotherapy optimization. Jpn J Clin Oncol. 2019;49(7):664\u201370.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"4173_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12886-019-1301-0","volume":"20","author":"SE Kim","year":"2020","unstructured":"Kim SE, Yang HJ, Yang SW. Effects of radiation therapy on the meibomian glands and dry eye in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. BMC Ophthalmol. 2020;20(1):24.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"4173_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/annonc\/mdj025","volume":"17","author":"K Tanimoto","year":"2006","unstructured":"Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim SW, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol. 2006;17(1):135\u201340.","journal-title":"Ann Oncol"},{"issue":"5","key":"4173_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/jjco\/hym031","volume":"37","author":"K Tanimoto","year":"2007","unstructured":"Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Watanabe T, Kobayashi Y, et al. Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Jpn J Clin Oncol. 2007;37(5):337\u201344.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"4173_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI-sponsored international working group. J Clin Oncol. 1999;17(4):1244.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4173_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International harmonization project on lymphoma revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4173_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4173_CR20","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3","volume":"52","author":"P Isaacson","year":"1983","unstructured":"Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma. Cancer. 1983;52(8):1410\u20136.","journal-title":"Cancer"},{"issue":"5","key":"4173_CR21","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood. 1994;84(5):1361\u201392.","journal-title":"Blood"},{"issue":"16","key":"4173_CR22","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1002\/cncr.25226","volume":"116","author":"JS Goda","year":"2010","unstructured":"Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Long\u2010term outcome in localized extranodal mucosa\u2010associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116(16):3815\u201324.","journal-title":"Cancer"},{"issue":"4","key":"4173_CR23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ijrobp.2011.04.052","volume":"82","author":"N Hashimoto","year":"2012","unstructured":"Hashimoto N, Sasaki R, Nishimura H, Yoshida K, Miyawaki D, Nakayama M, et al. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(4):1509\u201314.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"4173_CR24","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","volume":"30","author":"AJM Ferreri","year":"2012","unstructured":"Ferreri AJM, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, et al. Chlamydophila Psittaci Eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an International phase II trial. J Clin Oncol. 2012;30(24):2988\u201394.","journal-title":"J Clin Oncol"},{"issue":"3S","key":"4173_CR25","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1097\/IOP.0000000000001803","volume":"37","author":"Y Fujita","year":"2021","unstructured":"Fujita Y, Mimura M, Satou Y, Akioka T, Oku H, Ikeda T. Rituximab monotherapy for compressive optic neuropathy with giant ocular adnexal mucosa-associated lymphoid tissue lymphoma. Ophthal Plast Reconstr Surg. 2021;37(3S):S132\u20133.","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"8","key":"4173_CR26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3109\/02713683.2014.959605","volume":"40","author":"S Tuncer","year":"2015","unstructured":"Tuncer S, Tany\u0131ld\u0131z B, Basaran M, Buyukbabani N, Dogan O. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience. Curr Eye Res. 2015;40(8):780\u20135.","journal-title":"Curr Eye Res"},{"issue":"3","key":"4173_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cam4.5237","volume":"12","author":"K Mizuhara","year":"2023","unstructured":"Mizuhara K, Kobayashi T, Nakao M, Takahashi R, Kaneko H, Shimura K, et al. Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective study. Cancer Med. 2023;12(3):1\u201311.","journal-title":"Cancer Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04173-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04173-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04173-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:08:58Z","timestamp":1782468538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04173-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4173"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04173-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.M. received research funding from Ono, Janssen, Eisai, Chugai, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, Otsuka Pfizer, Loxo Oncology, Eli Lilly, Incyte Japan and honoraria from Ono, Nippon Shinyaku, Janssen, Eisai, Chugai, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, BioGene. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study design was approved by the ethics committee of the National Cancer Center prior to commencement. This study was conducted in accordance with the international ethical recommendations of the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}